<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>858</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11560772</PubmedId>
            <Abstract>Infection with Mycobacterium tuberculosis (MTB) remains a major cause of morbidity and mortality world-wide. An effective vaccination strategy is the immunization with plasmid DNA (pDNA), expressing an antigen (Ag) from a pathogen in vivo, which results in specific immune response against the encoded protein as well as the pathogen itself or cells infected with it. To test the ability to induce HLA-restricted T cell immune response against a mycobacterial antigen in humans by pDNA vaccination, we have used transgenic mice that express HLA class I (A*0201/Kb) or HLA class II (DRB1*0301) molecules. pDNA immunization with mycobacterial heat shock protein 65 (Mhsp65)-expressing plasmid (P3M.65) resulted in HLA-II-restricted, Ag-specific T cell-mediated immune responses characterized by proliferation and cytokine production. These T cell responses could be further augmented by the coinjection of P3M.65 and plasmid expressing murine GM-CSF. Furthermore, coimmunizing HLA-I transgenic mice with P3M.65 and a plasmid expressing murine IFN-gamma induced a specific cytotoxic T lymphocyte response restricted by HLA-A2. These results represent the first evidence of a concomitant in vivo induction of HLA class I- as well as class II-restricted T cell responses by pDNA immunization, which is induced or augmented by the codelivery of cytokine-expressing plasmids, supporting its potential use in clinical trials.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>1797-804</ArticlePages>
            <ArticleTitle>DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Charo</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Sundbäck</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Geluk</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Ottenhoff</LastName>
                    <ForeName>T</ForeName>
                </Author>
                <Author>
                    <LastName>Kiessling</LastName>
                    <ForeName>R</ForeName>
                </Author>
            </Authors>
            <Affiliations>Cancer Center Karolinska, Karolinska Hospital, S-17176, Stockholm, Sweden. Jehad_Charo@nih.gov</Affiliations>
            <ArticleChemicalList>Bacterial Proteins;Chaperonin 60;Cytokines;Epitopes;HLA-A2 Antigen;Peptides;Vaccines, DNA;heat-shock protein 65, Mycobacterium;Interferon-gamma;Chaperonins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Bacterial Proteins; COS Cells; Cell Division; Chaperonin 60; Chaperonins(genetics; metabolism); Cytokines(metabolism); Epitopes(chemistry); Genes, MHC Class I(genetics); Genes, MHC Class II(genetics); HLA-A2 Antigen(metabolism); Humans; Interferon-gamma(metabolism); Jurkat Cells; Mice; Mice, Transgenic; Mycobacterium(metabolism); Peptides(chemistry); Plasmids(metabolism); Protein Binding; T-Lymphocytes(metabolism); Transfection; Vaccines, DNA</ArticleMeshHeadingsList>
            <Journal>
                <Volume>12</Volume>
                <Issue>14</Issue>
                <Title>Human gene therapy</Title>
                <Issn>1043-0342</Issn>
                <MedlineTa>Hum Gene Ther</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Mhsp65p1-20</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MAKTIAYDEEARRGLERGLN</LinearSequence>
                        <StartingPosition>1</StartingPosition>
                        <EndingPosition>20</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA17397.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1773</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 1798</LocationOfData>
                <EpitopeId>41068</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>20</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Immunodominant epitope in source protein. Protein name stands for Heat shock protein 65. Also known as 60 kda chaperonin 2,  GroEl protein 2, Protein Cpn60-2, 65 kda Antigen, Cell wall protein A and Antigen A.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure  3</LocationOfData>
                        <TCellId>9468</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000609</OrganismId>
                                <Age>8-14 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>57</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>CAA17397.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>P3M.65</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>GM-CSF</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 immunizations every 3 wks, with 100 μg of plasmid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with an equal molar amount of  Hsp-encoding plasmid and control plasmid or Hsp-encoding plasmid and GM-CSF-encoding plasmid.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>57</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mhsp65p1-20</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MAKTIAYDEEARRGLERGLN</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>20</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA17397.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Splenocytes produced IFN-g in response to the peptide as measured by ELISA. Mice transgenic for human HLA class II and lacking endogenous MHC II expression were used to asses the ability of this MHC II restricted epitope in eliciting IFN-g production in splenocytes from mice immunized with Hsp65 plasmid DNA with or without coimmunization with GM-CSF-encoding plasmid. A similar but stronger response was obtained with GM-CSF, while proliferation of T cells after stimulation with peptide was similar for both groups of animals.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Mhsp65(9.21)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ALADAVKVT</LinearSequence>
                        <StartingPosition>21</StartingPosition>
                        <EndingPosition>29</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P0A520.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1773</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 1798</LocationOfData>
                <EpitopeId>2372</EpitopeId>
                <ReferenceStartingPosition>21</ReferenceStartingPosition>
                <ReferenceEndingPosition>29</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Immunodominant HLA-A2 restricted epitope. Protein name stands for Heat shock protein 65. Also known as 60 kda chaperonin 2,  GroEl protein 2, Protein Cpn60-2, 65 kda Antigen, Cell wall protein A and Antigen A.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>9473</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000579</OrganismId>
                                <Age>8-14 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>143</MhcAlleleId>
                                    <MhcAlleleId>122</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P0A520.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>P3M.65 gamma</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Interferon-Gamma</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 immunizations every 3 wks, with 100 μg of plasmid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>ALADAVKVT</LinearSequence>
                                            <StartingPosition>21</StartingPosition>
                                            <EndingPosition>29</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A520.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Immunization was performed with an equal molar amount of  Hsp-encoding plasmid and IFN-g-encoding plasmid. 3 wks after the final boost, splenocytes were cultured with syngeneic splenocytes pulsed with epitopic peptide for 6-8 days to establish the CTL lines.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>Jurkat-T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mhsp65(9.21)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALADAVKVT</LinearSequence>
                                        <StartingPosition>21</StartingPosition>
                                        <EndingPosition>29</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A520.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice transgenic for chimeric human-mouse HLA class I molecule were used to asses the ability of this MHC I restricted epitope in eliciting CTL activity in splenocytes obtained from mice immunized with Hsp65 plasmid DNA with coimmunization with IFN-g-encoding plasmid. No specific lysis is obtained without IFN-g coimmunization.  CTL lines  were incubated with target cells for 4 hrs. Target  cells are Jurkat cells, HLA-A*0201 negative, stably transfected with HLA-A*0201/Kb chimeric gene, and pulsed with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure  4</LocationOfData>
                        <TCellId>9472</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000579</OrganismId>
                                <Age>8-14 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>143</MhcAlleleId>
                                    <MhcAlleleId>122</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P0A520.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>P3M.65</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 immunizations every 3 wks, with 100 μg of plasmid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>ALADAVKVT</LinearSequence>
                                            <StartingPosition>21</StartingPosition>
                                            <EndingPosition>29</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A520.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Immunization was performed with an equal molar amount of  Hsp-encoding plasmid and control (empty) plasmid. 3 wks after the final boost, splenocytes were cultured with syngeneic splenocytes pulsed with epitopic peptide for 6-8 days to establish the CTL lines.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>Jurkat-T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mhsp65(9.21)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALADAVKVT</LinearSequence>
                                        <StartingPosition>21</StartingPosition>
                                        <EndingPosition>29</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A520.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>CTL lines did not lyse Jurkat cells ( HLA-A*0201 negative) stably transfected with HLA-A*0201/Kb chimeric gene and pulsed with peptide. Mice transgenic for chimeric human-mouse HLA class I molecule were used to asses the ability of this MHC I restricted epitope in eliciting CTL activity in splenocytes from mice immunized with Hsp65 plasmid DNA without coimmunization with the IFN-g-encoding plasmid. No specific lysis was observed without IFN-g coimmunization.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

